FAILURE OF FIRST-LINE TREATMENT THAT INCLUDED AN ANTI PD-(L)1 COMPOUND

Clinical trials for FAILURE OF FIRST-LINE TREATMENT THAT INCLUDED AN ANTI PD-(L)1 COMPOUND explained in plain language.

Never miss a new study

Get alerted when new FAILURE OF FIRST-LINE TREATMENT THAT INCLUDED AN ANTI PD-(L)1 COMPOUND trials appear

Sign up with your email to follow new studies for FAILURE OF FIRST-LINE TREATMENT THAT INCLUDED AN ANTI PD-(L)1 COMPOUND, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Not yet recruiting 1

New hope for liver cancer patients when first treatments stop working

Disease control Not yet recruiting

This study is testing whether adding an experimental drug called visugromab to standard cancer medications works better for people with advanced liver cancer. It's for patients whose first treatment that included immunotherapy has stopped controlling their cancer. Researchers wil…

Matched conditions: FAILURE OF FIRST-LINE TREATMENT THAT INCLUDED AN ANTI PD-(L)1 COMPOUND

Phase: PHASE2 • Sponsor: CatalYm GmbH • Aim: Disease control

Last updated Apr 04, 2026 10:05 UTC

FAILURE OF FIRST-LINE TREATMENT THAT INCLUDED AN ANTI PD-(L)1 COMPOUND

Get alerted when new FAILURE OF FIRST-LINE TREATMENT THAT INCLUDED AN ANTI PD-(L)1 COMPOUND trials appear

New hope for liver cancer patients when first treatments stop working